Emergent BioSolutions | EBS - Le Chiffre D'Affaires De Vente





Ventes Changement Date
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Akebia Therapeutics USD 57.34M 10.84M 2025-03
ALKERMES USD 384.5M 9.7M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amarin USD 49.67M 23.07M 2025-09
ANI Pharmaceuticals USD 247.06M 19.25M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Coherus Biosciences USD 7.6M 46.54M 2025-03
Emergent BioSolutions USD 276.6M 6.1M 2023-12
Exact Sciences USD 878.38M 27.38M 2025-12
Exelixis USD 598.66M 860K 2025-12
Glaxosmithkline GBP 11.52B 3.54B 2025-09
Heron Therapeutics USD 32.81M 3.21M 2024-09
Ionis Pharmaceuticals USD 203M 46M 2025-12
Ironwood Pharmaceuticals USD 47.71M 74.35M 2025-12
Lexicon Pharmaceuticals USD 1.65M 520K 2024-06
Lonza CHF 3.58B 63M 2025-06
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Myriad Genetics USD 209.8M 4.1M 2025-12
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pacira USD 196.87M 17.35M 2025-12
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Sanofi EUR 11.3B 1.13B 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Xoma USD 25K 5M 2024-09